MiR-29s: a Family of Epi-miRNAs with Therapeutic Implications in Hematologic Malignancies

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 May 14

PMID 25968566

Citations 77

Authors

Nicola Amodio

Marco Rossi

Lavinia Raimondi

Maria Rita Pitari

Cirino Botta

Pierosandro Tagliaferri

Pierfrancesco Tassone

Affiliations

Soon will be listed here.

Abstract

A wealth of studies has highlighted the biological complexity of hematologic malignancies and the role of dysregulated signal transduction pathways. Along with the crucial role of genetic abnormalities, epigenetic aberrations are nowadays emerging as relevant players in cancer development, and significant research efforts are currently focusing on mechanisms by which histone post-translational modifications, DNA methylation and noncoding RNAs contribute to the pathobiology of cancer. As a consequence, these studies have provided the rationale for the development of epigenetic drugs, such as histone deacetylase inhibitors and demethylating compounds, some of which are currently in advanced phase of pre-clinical investigation or in clinical trials. In addition, a more recent body of evidence indicates that microRNAs (miRNAs) might target effectors of the epigenetic machinery, which are aberrantly expressed or active in cancers, thus reverting those epigenetic abnormalities driving tumor initiation and progression. This review will focus on the broad epigenetic activity triggered by members of the miR-29 family, which underlines the potential of miR-29s as candidate epi-therapeutics for the treatment of hematologic malignancies.

Citing Articles

Unlocking the Potential of Circulating miRNAs as Biomarkers in Glioblastoma.

Suvarnapathaki S, Serrano-Farias A, Dudley J, Bettegowda C, Rincon-Torroella J Life (Basel). 2024; 14(10).

PMID: 39459612 PMC: 11509808. DOI: 10.3390/life14101312.

Significance of extracellular vesicles in orchestration of immune responses in infection.

Alipoor S, Elieh-Ali-Komi D Front Cell Infect Microbiol. 2024; 14:1398077.

PMID: 38836056 PMC: 11148335. DOI: 10.3389/fcimb.2024.1398077.

MicroRNA-Mediated Regulation of Histone-Modifying Enzymes in Cancer: Mechanisms and Therapeutic Implications.

Szczepanek J, Tretyn A Biomolecules. 2023; 13(11).

PMID: 38002272 PMC: 10669115. DOI: 10.3390/biom13111590.

Lowering Hippocampal miR-29a Expression Slows Cognitive Decline and Reduces Beta-Amyloid Deposition in 5×FAD Mice.

Mei Z, Liu J, Schroeder J, Weinshenker D, Duong D, Seyfried N Mol Neurobiol. 2023; 61(6):3343-3356.

PMID: 37989983 PMC: 11087195. DOI: 10.1007/s12035-023-03791-0.

GPER1 Activation Exerts Anti-Tumor Activity in Multiple Myeloma.

Gallo Cantafio M, Torcasio R, Scionti F, Mesuraca M, Ronchetti D, Pistoni M Cells. 2023; 12(18).

PMID: 37759449 PMC: 10526814. DOI: 10.3390/cells12182226.

References

Garzon R, Garofalo M, Martelli M, Briesewitz R, Wang L, Fernandez-Cymering C . Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A. 2008; 105(10):3945-50. PMC: 2268779. DOI: 10.1073/pnas.0800135105. View

Di Martino M, Gulla A, Gallo Cantafio M, Altomare E, Amodio N, Leone E . In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. PLoS One. 2014; 9(2):e89659. PMC: 3931823. DOI: 10.1371/journal.pone.0089659. View

Wu M, Fu J, Xiao X, Wu J, Wu R . MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer. Cancer Lett. 2014; 354(2):311-9. DOI: 10.1016/j.canlet.2014.08.031. View

Falkenberg K, Johnstone R . Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014; 13(9):673-91. DOI: 10.1038/nrd4360. View

Han Y, Garcia B . Combining genomic and proteomic approaches for epigenetics research. Epigenomics. 2013; 5(4):439-52. PMC: 4055025. DOI: 10.2217/epi.13.37. View

Kroeze L, Nikoloski G, da Silva-Coelho P, van Hoogen P, Stevens-Linders E, Kuiper R . Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies. Blood. 2012; 119(5):1318-9. DOI: 10.1182/blood-2011-07-365213. View

Di Fiore R, Drago-Ferrante R, Pentimalli F, Di Marzo D, Forte I, DAnneo A . MicroRNA-29b-1 impairs in vitro cell proliferation, self‑renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells. Int J Oncol. 2014; 45(5):2013-23. PMC: 4432724. DOI: 10.3892/ijo.2014.2618. View

Garzon R, Volinia S, Liu C, Fernandez-Cymering C, Palumbo T, Pichiorri F . MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008; 111(6):3183-9. PMC: 2265455. DOI: 10.1182/blood-2007-07-098749. View

Shen J, Zhang Y, Fu H, Wu D, Zhou H . Overexpression of microRNA-143 inhibits growth and induces apoptosis in human leukemia cells. Oncol Rep. 2014; 31(5):2035-42. DOI: 10.3892/or.2014.3078. View

10.

Cagnetta A, Adamia S, Acharya C, Patrone F, Miglino M, Nencioni A . Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. Leuk Res. 2014; 38(6):649-59. DOI: 10.1016/j.leukres.2014.03.006. View

11.

Bissels U, Bosio A, Wagner W . MicroRNAs are shaping the hematopoietic landscape. Haematologica. 2011; 97(2):160-7. PMC: 3269472. DOI: 10.3324/haematol.2011.051730. View

12.

Toyota M, Kopecky K, Toyota M, Jair K, Willman C, Issa J . Methylation profiling in acute myeloid leukemia. Blood. 2001; 97(9):2823-9. DOI: 10.1182/blood.v97.9.2823. View

13.

Tassone P, Neri P, Kutok J, Tournilhac O, Santos D, Hatjiharissi E . A SCID-hu in vivo model of human Waldenström macroglobulinemia. Blood. 2005; 106(4):1341-5. PMC: 1895190. DOI: 10.1182/blood-2004-11-4477. View

14.

Venkataraman S, Alimova I, Fan R, Harris P, Foreman N, Vibhakar R . MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One. 2010; 5(6):e10748. PMC: 2888574. DOI: 10.1371/journal.pone.0010748. View

15.

Chen B, Suen Y, Gu S, Li L, Chan W . A miR-199a/miR-214 self-regulatory network via PSMD10, TP53 and DNMT1 in testicular germ cell tumor. Sci Rep. 2014; 4:6413. PMC: 4166711. DOI: 10.1038/srep06413. View

16.

Guo J, Su Y, Zhong C, Ming G, Song H . Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle. 2011; 10(16):2662-8. PMC: 3219536. DOI: 10.4161/cc.10.16.17093. View

17.

Han Y, Park C, Bhagat G, Zhang J, Wang Y, Fan J . microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med. 2010; 207(3):475-89. PMC: 2839143. DOI: 10.1084/jem.20090831. View

18.

Roccaro A, Sacco A, Jia X, Azab A, Maiso P, Ngo H . microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood. 2010; 116(9):1506-14. PMC: 2938840. DOI: 10.1182/blood-2010-01-265686. View

19.

Chu L, Su M, Maggi Jr L, Lu L, Mullins C, Crosby S . Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress. J Clin Invest. 2012; 122(8):2793-806. PMC: 3408744. DOI: 10.1172/JCI63051. View

20.

Pekarsky Y, Croce C . Is miR-29 an oncogene or tumor suppressor in CLL?. Oncotarget. 2010; 1(3):224-7. PMC: 2951328. DOI: 10.18632/oncotarget.129. View